Abbott Laboratories

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Abbott Laboratories (ABT) Stock Could Be 24% Below Fair Value Before Earnings - simplywall.st

AI-generated analysis

📉 Abbott Laboratories stock is trading at $88.41, representing a 24% discount to a calculated fair value of $116.54.

📈 Analysts forecast earnings growth to $9.5 billion by June 2029, up from $6.3 billion today, with EPS expected to reach $5.45.

💰 The company has reaffirmed its quarterly dividend, providing a steady income stream for investors despite recent share price declines.

⚠️ Sustained pricing pressure in the diagnostics segment poses a potential risk to future earnings growth and margin expansion.

🌍 Macroeconomic headwinds including tariffs and currency swings could negatively impact Abbott's global revenue trajectory.

📊 The current P/E ratio of 24.6x is slightly elevated compared to the industry average of 24.4x but below a fair value estimate of 30.1x.

Bullish Signals
  • Stock is identified as undervalued by 24% with a fair value target of $116.54 versus the current price of $88.41.
  • Strong long-term earnings growth trajectory projected to reach $9.5 billion by June 2029 from current levels of $6.3 billion.
  • Company maintains a robust dividend track record which supports investor income strategies despite recent market volatility.
  • Current P/E ratio of 24.6x leaves room for re-rating towards an estimated fair value multiple of 30.1x.
Risk Factors
  • Sustained pricing pressure in the diagnostics segment could erode margins and challenge the projected earnings ramp.
  • Potential negative impact from tariffs and currency fluctuations may disrupt global revenue growth assumptions.
  • Significant analyst disagreement on long-term earnings potential, with bearish estimates as low as $7.2 billion by 2029.
Full Analysis
Simply Wall St analysis suggests Abbott Laboratories (ABT) stock is currently undervalued by approximately 24%, trading at $88.41 per share against a calculated fair value of $116.54. The report highlights that despite a recent decline in total shareholder return of 32.16% over the past year, the company maintains a strong dividend track record and diversified healthcare business mix. Analysts project Abbott's earnings to reach $9.5 billion by June 2029, representing significant growth from current levels, though there is notable disagreement on long-term potential with estimates ranging between $7.2 billion and $11.3 billion. The valuation model relies on steady top-line compounding, improving profitability margins, and a discount rate just under 8% to bridge the gap between current market price and fair value. While the current P/E ratio of 24.6x is slightly above the US Medical Equipment industry average, it remains below an estimated fair ratio of 30.1x, suggesting potential for re-rating. However, the analysis warns that sustained pricing pressure in diagnostics, prolonged impacts from tariffs, and currency fluctuations could challenge the company's earnings path and undermine the current undervaluation narrative ahead of its July 16 earnings report.